Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these agents enhance insulin release and inhibit glucagon output

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight reduction – they exhibit intriguing contrasts